Citius Oncology, Inc. CTOR Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Par or Stated Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s preferred stock, par or stated value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s preferred stock, par or stated value per share?
- Citius Oncology, Inc. (CTOR) reported preferred stock, par or stated value per share of $0 in Q1 2026.
- How has Citius Oncology, Inc.'s preferred stock, par or stated value per share changed year-over-year?
- Citius Oncology, Inc.'s preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Citius Oncology, Inc.'s preferred stock, par or stated value per share?
- Over 3 years (2022 to 2025), Citius Oncology, Inc.'s preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.